Further supply disruption of Genzyme's Cerezyme and Fabrazyme leads EMEA to give new temporary treatment recommendations; but no problems with Myozyme

23 April 2010

Troubled US biotech firm Genzyme has advised the European Union health regulator that the supply shortages of its rare disease drugs Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) are expected to continue at least until the end of September 2010, because of a new manufacturing problem.

Responding, the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) noted that temporary treatment recommendations to manage patients relying on these medicines during the ongoing supply shortages have been in place since June 2009 and have been regularly updated.

Patients could be switched to Shire's Replagal

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology